- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01271322
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG) (HICON)
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric Junction During Neoadjuvant Treatment: HICON Trial
Prospective, single-center, nonrandomized, explorative imaging study evaluating the value of PET as a predictor of histopathological response in metabolic non-responders Patients with resectable AEG (adenocarcinoma of the esophagogastric junction) type I and II (cT3/4 and/or cN+ and cM0)
Metabolic non-responders, showing a <35% decrease of SUV (standardized uptake value) two weeks after the start of neoadjuvant chemotherapy are eligible for the study and are taken to intensified taxane-based RCT (radiochemotherapy) before surgery. 18FDG-PET scans will be performed before (=Baseline) and after 14 days of standard neoadjuvant therapy as well after the first cycle of Taxotere/Cisplatin chemotherapy (=PET1) and at the end of intensified radiochemotherapy (PET2).
Tracer uptake will be assessed semiquantitatively using standardized uptake values (SUV). The percentage difference Delta SUV=100(SUVBaseline-SUVPET1)/ SUVBaseline will be calculated and assessed as an early predictor of histopathological response. In a secondary analysis, the association between the difference SUVPET1 - SUVPET2 and histopathological response will be evaluated.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Nationales Centrum für Tumorerkrankungen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Biopsy-proven adenocarcinoma of the distal oesophagus (AEG type I) or cardia (AEG type II) with or without metastases in local lymph nodes (tumor stage cT3/T4, cNX, and cM0 in the tumor-node-metastasis classification)
- Staging procedures include endoscopy, endoscopic ultrasound and computed tomography (CT) of the chest and abdomen.
- Eligible patients have to be fit for platin-containing chemotherapy
- Tumors must be potentially R0 resectable tumors during consecutive operation.
- Tumors must have demonstrated a minimal amount of FDG-uptake in the baseline PET-CT, defined as 18FDG-uptake in tumor at first examination > 1,35 x hepatic-SUV + 2 x standard-deviation of hepatic-SUV, and must be a metabolic non-responder under EOX, defined as a decrease of the SUVmax of <35% in a second PET on day 14 of chemotherapy.
Exclusion Criteria:
- Eastern Cooperative Oncology Group score >1
- Previous or secondary malignancy
- Life expectancy of less than 3 months
- Uncontrolled bleeding from the tumor
- Tumor infiltration of the airways
- Pregnancy
- Uncontrolled diabetes
- Patients are also ineligible if they have undergone previous chemotherapy, radiotherapy, or endoscopic laser therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between change in tumor metabolism (detected by PET) and histopathological response
Time Frame: PET Baseline, PET1 (before RCHT, week 5/6), histological examination of the resected tumor
|
The primary objective of the study is to evaluate the change in metabolic response - as measured by the relative difference delta SUV=100(SUVBaseline-SUVPET1)/ SUVBaseline in 18F-FDG uptake after 1 cycle of intensified taxan-based chemotherapy (PET1) - relative to the 18F-FDG uptake at the baseline examination, as a predictor of histopathological response in metabolic non-responders (assessed by PET 14 days after the start of neoadjuvant therapy).
|
PET Baseline, PET1 (before RCHT, week 5/6), histological examination of the resected tumor
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
distribution of change in tumor metabolism during the treatment in histological responders and non-responders
Time Frame: PET Baseline, PET1 (week 5/6), histological examination of the resected tumor
|
investigation of the distribution of change in tumor metabolism measured with PET Baseline and PET1(∆SUV = 100 (SUVBaseline - SUVPET1) / SUVBaseline) during the treatment in histological responders and non-responders according to the Becker Score (Histomorphology and grading of regression)
|
PET Baseline, PET1 (week 5/6), histological examination of the resected tumor
|
accuracy of the binary prediction rule reduction in the tumor metabolism >65% vs. <65% in histopathological responders vs. non-responders
Time Frame: Baseline, PET1 (week 5/6), histological examination of the resected tumor
|
accuracy of the binary prediction rule delta SUV >65% vs. <65% (reduction in the tumor metabolism >65% vs. <65 % between PET Baseline and PET1 in correlation with the histopathological regression accoring to the Becker Score
|
Baseline, PET1 (week 5/6), histological examination of the resected tumor
|
association between change in tumor metabolism before/after radiochemotherapy and histopathological response
Time Frame: PET1 (week 5/6), PET2 (before resection), histological examination of the resected tumor
|
association between tumor metabolism before/after radiochemotherapy (∆SUV = 100 (SUVPET1 - SUVPET2) / SUVPET1) and histopathological response according to the Becker Score (histomorphology and grading of regression)
|
PET1 (week 5/6), PET2 (before resection), histological examination of the resected tumor
|
association between change in tumor metabolism between PET Baseline and PET1 and overall survival as well as disease-free survival
Time Frame: Baseline, PET1 (week 5/6), Follow Up (q3 months during the first post-operative year, q6 months during the 2nd/3rd postoperative year)
|
association between change in tumor metabolism between PET Baseline and PET 1 (∆SUV = 100 (SUVBaseline - SUVPET1) / SUVBaseline)and overall survival as well as disease-free survival
|
Baseline, PET1 (week 5/6), Follow Up (q3 months during the first post-operative year, q6 months during the 2nd/3rd postoperative year)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sylvie Lorenzen, MD, Dep. Of Medical Oncoloy, National Center for Tumor Diseases
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT200811021017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinomas of the Esophagogastric Junction
-
H. Lee Moffitt Cancer Center and Research InstituteAventis PharmaceuticalsTerminatedEsophageal Adenocarcinomas | Adenocarcinomas of the Gastroesophageal JunctionUnited States
-
Accelerated Community Oncology Research NetworkAmgenTerminatedGastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal StomachUnited States
-
Technical University of MunichCompletedAdenocarcinoma of the Esophagogastric JunctionGermany
-
Fujian Medical University Union HospitalCompletedAdenocarcinoma of the Esophagogastric JunctionChina
-
Yu jirenRecruitingAdenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric Junction | Proficient Mismatch RepairChina
-
St. James's Hospital, IrelandUnknownBarrett Esophagus | Siewert Type II Adenocarcinoma of Esophagogastric Junction | Oesophagus Cancer | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric JunctionIreland
-
Universitätsklinikum Hamburg-EppendorfCompletedCarcinomas of the Esophagogastric JunctionGermany
-
Yu jirenRecruitingAdenocarcinoma of the Stomach | Mismatch Repair Deficiency | Adenocarcinoma of Esophagogastric JunctionChina
-
Genta IncorporatedUnknownAdenocarcinoma of the Stomach | Adenocarcinoma of Esophagogastric JunctionUnited States, Korea, Republic of
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingSiewert Type II Adenocarcinoma of Esophagogastric Junction | Esophagogastric Junction AdenocarcinomaChina
Clinical Trials on neoadjuvant radiochemotherapy in metabolic non responders
-
University Hospital, BordeauxActive, not recruiting
-
Austrian Breast & Colorectal Cancer Study GroupHoffmann-La RocheCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
City of Hope Medical CenterOSI PharmaceuticalsCompletedStage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
PfizerTerminatedLiver Neoplasms | Colorectal NeoplasmsUnited States
-
Julio RamirezUniversity of LouisvilleTerminatedOsteomyelitisUnited States